Compare iShares MSCI China ETF (MCHI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Natera Inc. Common Stock — how do they compare? iShares MSCI China ETF trades at $51.22 (market cap $5.82B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 9.8× iShares MSCI China ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 65 Days and Natera Inc. Common Stock for 0 Days on average.
| MCHI | NTRA | |
|---|---|---|
Market Cap | $5.82B | $57.03B |
Volume | 1,436,013 | 1,131,157 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $425.64 |
52-Week Low | $50.48 | $179.42 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $52.135, down slightly by 0.03% with a bearish technical signal from moving averages. The ETF faces mixed sentiment amid China's economic challenges including industrial overcapacity and weak domestic consumption, though corporate profits surged 26% in Q2. Recent news highlights potential trade developments from upcoming U.S.-China talks and concerns over export controls on AI and semiconductors.
The outlook remains cautious with significant discount to US indices offering potential value, but risks from global trade tensions and China's economic rebalancing persist. Institutional activity shows mixed positioning, with some funds increasing stakes while others reduce exposure, reflecting uncertainty in Chinese equity markets.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
